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Objectives: Investigators hypothesized that cancer stem
cells (CSCs) could play a role in determining cancer
progression by metastasizing to cervical lymph node (N+)
and then influencing prognosis of head and neck squamous
cell carcinomas (HNSCCs) patients.
Design: To identify CSCs in HNSCCs and their clonogenic
capacity.
Setting: In vitro study.
Participants: Putative CSCs from 29 primaryHNSCCs and
19 corresponding node metastases were analyzed.
Main outcome measures: Immunohistochemical (IHC)
was performed, and CSCs’ clonogenic in vitro capacity was
tested; ones epithelial nature of cancer cells forming colonies
was confirmed by a second IHC, fluorescence-activated cell
sorting (FACS) analysis helped in counting CD44/CD133-
CSCs markers percentage expression in HNSCC tumour-
derived cultures.
Results: Immunohistochemical showedCD44 (93.1%) and
CD133 (10.34%) expression; FACS-analysis showed the
enrichment of CD44/CD133 cancer cells, with the highest
clonogenic capacity of CD44+-subpopulation; a higher
CD44 rates were documented from N+ subcultures than
from original tumours (P < 0.05).
Conclusions: A putative cancer stem-like cell population is
detectable in HNSCCs, and our findings show their in vitro
clonogenic capacity by demonstrating that CD44+-cultured
cells are the main population proliferating obtained by N+
HNSCC metastases, emphasizing their possible role in
tumour progression.
Head and neck squamous cell carcinoma accounts approx-
imately 500 000 new cases per year.1 Despite advances in
treatment, survival rates have not improved significantly in
more than 30 years; mortality is mainly related to metasta-
ses’ development, therapy resistance, local and regional
recurrences. Clinical and pathological prognostic factors
such as tumour stage, lymph node involvement, post-
surgical positive margins and histological grade, lack sensi-
tivity and accuracy in the clinical setting and, with the
exception of disease stage, are infrequently used to guide
treatment decisions.2–4 Better understanding of biologic
behaviour of Head and neck squamous cell carcinoma is
required to define novel therapeutic strategies.
Over the last two decades, advances in tumour biology
have led to identify in many cancers, including Head and
neck squamous cell carcinomas, a subpopulation of cancer
cells with stem properties, which is able to undergo
self-renewal and differentiation, to initiate tumourigenesis
and hence to support tumour growth, progression and
chemo-/radioresistance.5,6 This cancerogenesis hypothesis
considers that stem cells or cells that acquired the self-
renewal ability tend to accumulate genetic alterations over
long periods of time, evading the strict control of their
microenvironment and giving rise to tumoural evolution.7
Numerous hypothesis exists about the origin of cancer stem
cells,8 and the difficulty in studying normal stem cells and
cancer stem cells has led to use empirical models of isolation
of cancer stem-like cells by specific cell-surface markers and
the characterisation of their behaviour by in vitro cultures
and in vivo self-renewal assays. CD44 and CD133 are the
main cell-surface markers associated with stem cell charac-
teristics.9–12 CD133 or prominin 1 (PROM1)was discovered
as a marker of normal hematopoietic stem cells, and its
power to identify cancer stem-like cells has been confirmed
recently.13 CD133’s display has been found in several solid
tumours of different anatomical sites, head and neck district
included.14–18 CD44, receptor of hyaluronic acid, seems to be
involved in cell adhesion, migration andmetastasis of cancer
cells.19 Various CD44 variant isoforms are differentially
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expressed in normal and malignant cells. Overexpression of
several CD44 variant isoforms has been associated with
tumour progression, suggesting that these isoforms may
have unique signalling properties. Several human tumours
show CD44 altered expression and translation, with CD44
changing during tumour progression.20–22 All of these
investigations suggest that different stem cell markers could
be expressed in various tumours by the cancer stem cells, but
their significance remains to be determinated. Therefore, it is
possible that each solid tumour could show a specific cancer
stem cell phenotype.23
The main published articles show the presence of a diffuse
positivity of CD44 antigen (>95%) in Head and neck
squamous cell carcinomas, which identify cancer cells with
clonogenic in vitro properties, while few CD44 and CD133
co-expressing cells are encountered (<10%).24
The role of cancer stem cells in metastasis is not clear yet,
but it is likely they are the cells responsible for their
development. Cancer stem cells would migrate and attach a
new location, and local conditions should able to stimulate
and support cancer stem cells and the production of their
progenitors.25–27 Then, an evaluation of the cancer stem
cells’ role in metastasis will produce new insights into this
process andwill lead to new treatments in order to prevent or
eliminate metastatic disease.
It is well known that cancer stem cells and normal stem
cells share someproperties, and on the basis of these remarks,
our aim was, first of all, to investigate the potential role of
cancer stem cells in tumour progression, by detecting the
presence of phenotype stem-like characteristics, by CD44
and/or CD133 antigens expression, in cancer specimens
from Head and neck squamous cell carcinomas. Moreover,
the parallels existing between normal somatic stem cells and
cancer stem cells suggest that the principles of normal stem
cell biology may be usefully applied to studies of cancer stem
cell identification and their roles in tumour development
and progression,28 and current methods for determining
whether cells isolated from solid tumour are cancer stem cells
consist of purification of these one based on such stem
properties as their ability to form spheres in culture.12,29,30
To better address this issue, we harvested from both primary
and lymph node metastases (N+) tumour surgical speci-
mens, cancer cell cultures to comparatively evaluate their
phenotype and clonogenic in vitro potential.
Materials and methods
The study was conducted on tumour specimens, obtained in
sterile conditions at the operating table, during the tumour
surgical excision from 29 consecutive patients affected by
primary and not previously treated Head and neck squa-
mous cell carcinoma, from April 2008 to July 2009 at our
institution. Patients previously treated by surgery, radio-
therapy and/or chemotherapy, tumour recurrence or per-
sistence, second primary tumour, synchronous or
metachronous tumours were all considered as exclusion
criteria.
The study design included (i) immunohistochemical
analysis on sections from primary Head and neck squamous
cell carcinoma and their lymph node metastasis to provide
the presence of cancer cells with stem-like phenotype
characteristics (CD44+ CD133+) and the evidence for a
developmental hierarchy in Head and neck squamous cell
carcinoma, such as in normal epithelial tissue; (ii) ones
identified stem-like cancer cells, the second step was to
perform in vitro cultures of spheres cells by testing the cancer
stem-like clonogenic capacity; (iii) a second immunohisto-
chemical study on cell cultures was used to exclude a possible
component of flogist cells and to confirm the epithelial
nature of cells forming colonies; (iv) fluorescence-activated
cell sorting analysis was used to count the CD44+ CD133+
cancer cells percentage forming cell colonies.
Ethical considerations
This study was approved by the Florence Universitarian
Hospital IRB, and all participants signed an informed
consent agreement. All patients gave their consent to
undergo the procedure and to treat their personal details.
No more to declare.
Immunohistochemistry
Frozen sections from neoplastic fragments were embedded
in cold acetone for 1 min and dried for 10 min at 37°. The
sections were rinsed in distilled water for 5 min and then in
phosphate buffer (pH 7.4); immunohistochemical studies
were performed on formalin-fixed, paraffin-embedded tis-
sue sections (5 lm of thickness) using the technique of
streptavidin–biotin–peroxidase (Labvision Co, Freemont,
CA, USA).
Immunohistochemistry-CD133. CD133 primary antibody
(Miltenyi Biotech, Bologna, Italy) was used at a dilution of
1 : 100 with incubation for 1 h in environmental temper-
ature. Further, these sections were counterstained. Sections
without primary antibodies served as negative controls.
Immunohistochemistry-CD44. Specimens were depar-
affinazed with xylene, rehydrated in serial graded water–
ethanol solution and then rinsed in 3% hydrogen peroxide
solution to eliminate endogenous peroxidase. The sections
were then heated in amicrowave oven for 35 min at 300W in
citrate buffer (0.1 Mol, pH 6.0), placed in a phosphate-
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buffered saline (pH 7.6), and then CD44, CD44v3 and
CD44v6 monoclonal primary antibodies were applied (R &
D Systems, Abingdon, UK) at a dilution 1 : 1000 at 4°
overnight. Sections were counterstained. Sections without
primary antibodies served as negative controls.
Cell cultures
We grouped the establishment of cell cultures to characterise
the cancer cells’ biology and their potential stem properties.
Biopsy-proven squamous cell carcinomanature of the primary
tumour or of the corresponding lymph nodemetastasis where
it was present was surgically resected from each patient and
immersed into sterile phosphate-buffered saline (pH7.4)
supplemented with pen–strep (100 U/mL pen 100 lg/mL
strep, Euroclone) and amphotericin (250 lg/mL, Euroclone)
and sent to the department of Experimental Pathology and
Oncology. Specimens were cut into small pieces (1 mm) and
shaked for 4 h at 37°C in phosphate-buffered saline supple-
mented with 1 mg/mL collagenase III (Biochrome AG), to
perform enzymatic digestion. Each digestion was divided into
two aliquotes that were centrifuged at 1100 rpm: revolutions
perminute (10 min), to remove the digestion buffer. Onewad
was resuspended in freezingmedium (90% FCS, 10%DMSO)
and stored under liquid nitrogen. This sample was used as
‘time 0’ (early culture), as it is representative of biopsy whole
cell population. Cells from the second wad were resuspended
in culture medium (DMEM supplemented with 20% FCS and
pen–strep and amphotericine, as above), seeded in a Petri dish
and incubated at 37°C in a 5% CO2 humidified atmosphere.
After a few days, adherent cells were rinsed with phosphate-
buffered saline and fresh medium wad added. When subcon-
fluent, cells were harvested by trypsin–EDTA treatment
(0.5 : 0.2 mg/mL), resuspended in freezing medium and
stored under liquid nitrogen. For typisation, an aliquote of
cellswere seededonaglass slide.When subconfluent, cellswere
fixed for 10 min with ice-cold 90% ethanol for immunohis-
tochemistry. Major difficulties in setting up H&N cancer cell
lines from biopsies were sterility failure and fibroblast
contamination. Sterility was achieved in about 40% of
cultures.9–12 After 3 weeks of culturing, we obtained ‘late
culture’.
Immunohistochemistry on cell cultures
Immunohistochemistry of early and late cell cultures used
the same antibodies against CD44 and CD133.
Immunohistochemistry-CD133. CD133 primary antibody
(Miltenyi Biotech) was used at a dilution of 1 : 100 with
incubation for 1 h in environmental temperature.
Immunohistochemistry-CD44. CD44, CD44v3 and CD44v6
monoclonal primary antibodies were applied (R & D
Systems) at a dilution 1 : 1000 at 4° overnight.
Moreover, we verified the epithelial nature of cell
cultures, by detecting the presence of cytoplasmic epithelial
cytokeratin.
Fluorescence-activated cell sorting analysis
Each obtained Head and neck squamous cell carcinoma
cultures were washed with phosphate-buffered saline and
fixed with phosphate-buffered saline supplemented with 3%
paraformaldehyde (10 min, 4°C) and incubated (i) none,
(ii) anti-CD133-PE (clone-AC133; Miltenyi Biotec), (iii)
anti-CD44-APC (clone-IM7; eBioscience, San Diego, CA,
USA) and (iv) both anti-CD133-PE and anti-CD44-APC.
Cell staining was in accordance withmanufacturer’s instruc-
tions. Cytofluorimetric analysis was carried out with a
FACSCanto apparatus (Becton Dickinson, La Jolla, CA,
USA) Coherent Sapphire Solid State laser (k = 488 nm) and
a JDS Uniphase HeNe laser (k = 633 nm), computed by the
BD Diva 6.1.2. software (Becton Dickinson). Sections
without primary antibodies served as negative controls.
Statistical analysis
Results were evaluated using analysis of variance, chi-square
and Student t technique for paired data. Statistical signifi-
cance was set for P-values P < 0.05.31
Results
Among 29 Head and neck squamous cell carcinoma
patients, 19 were male and 10 female, with a mean age of
63.08 years (60.06  14.05 SD years for male and
66.10  10.88 SD for female). All of these patients were
affected by newly diagnosed Head and neck squamous cell
carcinoma. Head and neck squamous cell carcinomas
originated from the oral cavity in 12 (two of these were
from the alveolar process, two from the buccal mucosa, four
from retromolar trigone, four oral tongue), in six cases from
oropharynx (three of these were from the tonsil, one of the
soft palate, one from tongue base and one from the
vallecula), seven were laryngeal tumours, and in four cases,
we studied the cervical lymph nodemetastases from primary
unknown. Clinical data were collected, including age, sex,
alcohol and tobacco consumption (cut-off = almost 10
pack/years), cancer family history, comorbidities (liver
pathology, cardiovascular pathology, glaucoma, mellitus
diabetes); TNM stages and the primary tumour sites are
shown in Table 1.
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Immunohistochemistry
CD133. Immunohistochemical study showed positivity for
CD133 in only three of the 29 cases analysed (10.34%). The
percentage of positive tumour cells was variable (from five to
30% of counted cells), indicating that only a fraction of the
total tumour cells expressed this marker. In our series, we
found the highest CD133 expression in tumour specimens
derived from cervical lymph node metastases (10.5%, two of
19 N+), while the CD133 primary tumour specimens
expression found was of 3.4% (one case of 29 primary
tumour specimens) (P < 0.05).
CD44s. It was overexpressed in 27 of the 29 cases examined
(93.1%). In particular, all three tumours CD133 positive
were CD44 positive too. Unlike CD133, immunohistochem-
ical showed high rate of CD44-positive cancer cells, either
from biopsy of primary tumour or from metastases.
Moreover, we obtained a strong CD44-positive basal cell
layers in tumours moderately or highly differentiated, while
in the more keratinised and differentiated cells, this marker
was absent (Fig. 1).
The immunohistochemical analysis of consecutive
tumour specimen slices (Fig. 2) suggests a potential coex-
pression of CD44/CD133 antigens.
Cell cultures
The primary Head and neck squamous cell carcinoma cells
isolated from six patients (Table 2) could be passed formore
than 16 passages without loss of growth, viability or the
morphological features of the parental cells. Free-floating
spherical colonies were obtained from tumour biopsies
taken from primary tumours in four of the six cases (T1N1,
Table 1. Clinical parameters, TNM stage and primary tumour
sites.
Clinical parameters Number of patients: (%)
Sex
M 19 (65.5)
F 10 (34.5)
Age
M 60.06  14.05 SD
F 66.10  10.88 SD
Alcohol consumption
Yes 11 (38)
No 18 (62)
Tobacco consumption
Yes, p/y = 25.62  29.93 SD 21 (72.4)
No 8 (27.6)
Alcohol + tobacco consumption
Yes 11 (38)
No 18 (62)
Cancer family history
Yes 15 (51.7)
No 14 (48.3)
Comorbidities
Yes 13 (44.8)
No 16 (55.2)
29 (100)
TNM
T1 T2 T3 T4a T4b Tx Total
N0 3 4 2 9
N1 4 6 1 1 12
N2a 2 1 1 4
N2b 1 1 1 3
N2c 1 1
N3
Total 7 14 3 1 1 3 29
Primary sites Number of patients
Oral cavity 12
Alveolar process 2
Oral mucosa 2
Retromolar trigone 4
Oral tongue 4
Oropharynx 6
Tonsil 3
Soft palate 1
Tongue base 1
Vallecula 1
Larynx 7
Supraglottic 3
Glottic 2
Subglottic 2
TxN+ 4
Fig. 1. Strong CD44-positive basal cell layer suggesting a clear
topographical cancer stem cells redistribution. While this marker
was absent in the more keratinised and differentiated cells.
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T2N0, T4bN2b, T4aN1) and from the lymph node metas-
tases in two of the six cases (TxN1M0 andT2N2b). Instead of
getting a total of 12 cultures, including six early and other six
late cultures, the final number was of only eight cultures
overall, of which six were early cultures and only two were
late cultures, because of bacterial contaminations and that
the remaining subcultures did not reach the optimal period
of incubation that they can refer to various studies planned.
Immunocytochemistry on cell cultures
We verified the epithelial nature of cell cultures, by detecting
the presence of cytoplasmic epithelial cytokeratin, to exclude
the successful replication of the cellular inflammatory
component and/or fibroblasts (Fig. 3). Then, the immuno-
histochemical analysis on cell cultures searching for both
markers’ expression, CD44 and CD133, confirmed the
highest expression of CD44 in these cancer cell culture
populations, analogously to immunohistochemical on fresh
tumour specimens.
Fluorescence-activated cell sorting analysis
Fluorescence-activated cell sorting analysis was performed
on six early cultures (Table 2), and on their late cultures,
obtained after 3 weeks of cell suspension. We looked at the
percentage of CD133 andCD44 expression in each culture by
fluorescence-activated cell sorting.
We did not detect CD133 expression on early and late
cultures; conversely, CD44 was largely expressed (Table 2).
We noticed an increase of CD44 expression during the
3-week cell suspension; T early ‘time 0’ cultures presented a
CD44 expression proportion of 56.12  34.47% SD (range:
25.7–97.8%) which reached, in 3 weeks (late cultures), the
93.8  8.94% SD (range: 83.5–99.5%) (Fig. 4). Moreover,
we noticed that N+ early cultures started at ‘time 0’ with a
(a)
(b)
Fig. 2. CD44 and CD133 co-expression.
Table 2. Characteristics of the six patients from whom cell cultures have been obtained and cultures’ expression of CD44 and CD133
Case 1 2 3 4 5 6
Age/Sex 63/F 31/M 65/M 63/M 68/F 58/M
Smoke (p/y) 35 4 12 100 0 22
Alcohol Yes No Yes Yes No No
Initial stage (AJCC 2005) T1N1M0 T2N0M0 TxN1M0 T4bN2bM0 T2N2bM0 T4aN1M0
Tumour site Tongue
margin
Tongue
margin
Lymph node
metastasis
Retromolar
trigone
Larynx Oral mucosa
Comorbidities No No Yes No No No
Immunohistochemical analysis
CD44 + + + + + 
CD133      
Cultures obtained from
T Yes Yes No Yes No Yes
N No No Yes No Yes No
Fluorescence-activated cell sorting analysis CD44 (%)
Early culture 25.7 30.1 98.4 71.1 98.2 97.8
Late culture 99.6 83.5    
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higher CD44 percentage of 98.33%  0.14 SD (range: 98.2–
98.4%) (P < 0.05), highlighting a CD44 overexpression in
early cultures from the lymph node metastasis (Fig. 4c).
Discussion
In this study, we evaluated the expression of CD44 and
CD133 in biopsy specimens and early cell cultures from
Head and neck squamous cell carcinoma by immunohis-
tochemical assay and fluorescence-activated cell sorting
analysis. We found a high percentage of CD44 expression
(93.1%) both in tumour specimens and in derived early
cell cultures, confirming the diffuse distribution of this
marker in Head and neck squamous cell carcinomas and
a lower CD133 expression (10.34%), similar to that
reported in literature.9,10,32 Moreover, we established a
successful rate of free-floating spherical colonies from
primary tumours (21%, four out 29) and from their
corresponding cervical lymph node metastases (N+)
(10.5%, 2 out 19), higher than other Head and neck
squamous cell carcinomas studies.33
In this setting, we documented the increasing expression
of CD44+ subpopulations through several in vitro cultural
steps, showing a clear clonogenic property (Fig. 4), that is
their capacity to regenerate themselves through cell division.
We also identified that cell clonogenicity wasmore evident in
metastatic lymph node cell cultures than in those from
primitive tumour, suggesting a possible more aggressive
attitude of CD44-positive cancer stem cells obtained from
N+ specimens (Fig. 4c) and its potential involvement in
metastatic process.
Fig. 3. Cell-specific cytokeratin-positive cancer cell cultures.
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Fig. 4. Here, the most representative fluorescence-activated cell sorting analysis obtained for each different sample is reported. (a) T early
culture with CD44 expression of 25.7%; (b) T late culture with CD44 expression of 99.6%; (c) CD44 expression in immunohistochemical
early culture from lymph node metastasis.
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According to recent report,34 we demonstrated that Head
and neck squamous cell carcinoma-driven squamouspheres
exhibit some of cancer stem cell-like criteria, that is: (i)
cancer stem cells-surface markers: CD44/CD133, (ii) squa-
mouspheres-forming capacity, (iii) enrichment in CD44
expression at fluorescence-activated cell sorting analysis
after in vitro culture passages and (iv) evidence of an existing
starting subpopulation with near 98% expression of CD44
antigene in cervical lymph node metastases cultures.
Our findings regarding the high enrichment and the in
vitro clonogenicity of CD44+ cells by N+ specimens com-
pared with results from primary tumour specimens are in
agreement with increased motility in CD44-positive cancer
cells in Head and neck squamous cell carcinoma, as recently
reported by Davis SJ and Brown RL,35,36 highlighting a
central role of CD44+ cancer stem cells in Head and neck
squamous cell carcinomas progression and locoregional
spreading. Accordingly, in a recent study on breast cancers,37
the standard isoform of CD44 antigen (CD44s) seems to be
critical for regulating epithelial–mesenchymal transition,
which is a process by which epithelial cells lose their polarity
and are converted to a mesenchymal phenotype, and this
process seems to be abnormally activated during cancer
metastasis and recurrence. This process has been also
regarded as the critical event to induce morphogenetic
changes during embryonic development, organ fibrosis and
tumour metastasis.38 In fact, the increased motility of
metastatic cancer cells is typical of cells undergoing epithe-
lial–mesenchymal transition.36 Taken together, these data
suggest that regulation of CD44 expression could contribute
to epithelial–mesenchymal transition and cancer progres-
sion, and it appears that cancer stem cells may have these
capabilities; furthermore, our results might explain the
enrichment of CD44+ cancer stem cells in lymph node
metastases in in vitro study.37
Unfortunately, in this preliminary analysis, we did not
identify CD133-positive cells in our limited number of cell
cultures established. Few recent studies,10,33 mainly analy-
sing in vitro Head and neck squamous cell carcinoma cell
lines, have reported that CD44+/CD133+ cells are those with
the best chance to represent the true cancer stem cell
population also inHead andneck squamous cell carcinomas,
as well as in other human solid tumours.39–43 The lack of
fluorescence-activated cell sorting identification of this
specific subpopulation in our cultures seems to reflect the
low presence of this cancer stem cell marker in Head and
neck squamous cell carcinoma initiating tumour cells as
reported in literature.10,33 Another possible explanation of
this lack is that it would be due to the coincidence that
unfortunately all the harvested cell cultures were obtained
from CD133-negative Head and neck squamous cell carci-
nomas, thus suggesting at least a less chance to detect or
expand in vitro this specific and very rare subpopulation of
Head and neck squamous cell carcinoma cells. Accordingly,
others reported that CD133 marker is less expressed than
CD44 in Head and neck squamous cell carcinomas, and its
sensibility of identify cancer stem cells is still object of
discussion. There are few studies in literature which have
tried to identify cancer stem cells in Head and neck
squamous cell carcinoma using CD133 surface marker, and
they succeeded in <10% of cases analysed. At variance, only
CD44 as stem cell marker constitutively expressed on the
surface of all permanent Head and neck squamous cell
carcinoma cell lines, and thus, it may play a key role in
establishment of permanent Head and neck squamous cell
carcinoma cell lines.44 Anyway, some authors confirm
CD133 as cancer stem cells marker. In fact, Harper et al. 33
tested stem cell patterns in Head and neck squamous cell
carcinoma cell lines through in vitro analysis by performing
fluorescence-activated cell sorting analysis of potential stem
cell markers (CD44, CD133 and CD29) in six Head and neck
squamous cell carcinoma cell lines, and they obtained a
subpopulation with high expression of CD44 for each cell
line, while the CD133 expression was less intense. Yu et al. 45
tried to identify the highly tumourigenic cell population in
laryngeal carcinoma cells obtained from primary tumours
using CD44/CD133 cell population. Wei et al. 12 identified
CD133-positive cancer cells with stemproperties in laryngeal
cancer cell lines (Hep-2); also, Okamoto et al. 10 proposed
CD133 antigen as a co-marker together with CD44 and
ABCG2. Another recent paper in human oral squamous
cancer analysed the cancer stem cells CD133-positive role in
determining chemoresistance properties, further suggesting
a possible key role of these cancer stem cells inHead and neck
squamous cell carcinoma tumourigenesis.46 More recently,
Chikamatsu et al. 47 reported that CD44+ head and neck
cancer stem cells were resistant to various apoptosis stimuli.
By our preliminary and limited results, we can add that
tumour specimens showing the highest CD133 expression by
immunohistochemical assay were those from cervical lymph
node metastases (10.5%, 2 of 19 N+ cases) (P < 0.05). This
result, together with our immunohistochemical, cell cultures
and fluorescence-activated cell sorting analyses, could help
in identifying cell populations with morphologic stem cell-
like characteristics. Furthermore, this study suggests that
CD44+ and CD133+ cells are detectable in Head and neck
squamous cell carcinomas with a higher frequency in lymph
node metastases than in primary tumours, thus suggesting a
some role in Head and neck squamous cell carcinoma
progression. This hypothesis of metastasising capacity and
aggressive attitude of cancer stem cells, mainly of CD44+
cancer stem cell population, is further supported by our in
vitro study, demonstrating that CD44+-cultured cells have
the highest clonogenic capacity and are the main population
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proliferating in in vitro cultures obtained by N+ Head and
neck squamous cell carcinoma metastases.
Obviously, these preliminary results need to be confirmed
in a larger series and need to be confirmed in experimental
animal models.
Keypoints
• A putative cancer-stem-like-cell-population is detect-
able in HNSCCs.
• IHC and fluorescence-activated-cell-sorting-(FACS)
analysis helped in counting CD44/CD133-CSCs mar-
kers percentage expression in HNSCC tumor-derived
cultures and in identifying their clonogenic capacity.
• CD44+ cultured cells are the main population
proliferating obtained by N+ HNSCC metastases,
emphasizing their possible role in tumor progression.
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